Fang Binbin, Liu Fen, Luo Junyi, Song Ning, Liu Chang, Ji Wei, An Xin, Xie Qian, Yang Yining, Li Xiaomei
State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
The First Department of Coronary Heart Disease, Heart Center of the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
Diabetes Metab Syndr Obes. 2025 Aug 25;18:3031-3040. doi: 10.2147/DMSO.S535325. eCollection 2025.
Data on the effect of GLP-1RA treatment on the long-term prognosis of patients with diabetes after percutaneous coronary intervention (PCI) are scant. The purpose of this study was to evaluate the effect of GLP-1RA treatment on the long-term prognosis in T2DM patients after PCI.
Data on T2DM patients who underwent PCI from January 2019 to December 2020 were retrospectively analyzed. Clinical data and the use of hypoglycaemic drugs were collected. Patients were divided into 2 groups based on whether they were treated with GLP-1RAs: the control group and the GLP-1RA group. PSM was used to match the control group at a 1:1 ratio. Survival curve and univariate and multivariate Cox regression analyses were used to compare the effects of GLP-1RA treatment on prognosis.
A total of 981 patients were enrolled, and 277 pairs (554 patients) were matched with propensity scores. The balance between two groups improved after PSM (>0.05). Compared with the control group, patients in the GLP-1RA group had lower TC, LDL-C, and HbA1c levels (<0.05). After 24 months of follow-up, a total of 93 patients experienced adverse cardiovascular events. The survival curve revealed that the event-free survival rate in the GLP-1RA group was greater than that in the control group (log rank =0.012). Univariate and multivariate Cox regression analyses revealed that BMI (HR: 1.055, 95% CI=1.007-1.105), HDL-C levels (HR: 0.236, 95% CI=0.095-0.583) and GLP-1RA use (HR: 0.617, 95% CI=0.403-0.943) were independent influencing factors of post-PCI major adverse cardiovascular event (MACE) risk in T2DM patients (<0.05).
GLP-1RA treatment demonstrates cardiovascular benefits in T2DM patients following PCI, effectively reducing the risk of MACE, and enhancing long-term prognosis.
关于胰高血糖素样肽-1受体激动剂（GLP-1RA）治疗对经皮冠状动脉介入治疗（PCI）后糖尿病患者长期预后影响的数据较少。本研究旨在评估GLP-1RA治疗对PCI术后2型糖尿病（T2DM）患者长期预后的影响。
回顾性分析2019年1月至2020年12月接受PCI的T2DM患者的数据。收集临床数据和降糖药物使用情况。根据患者是否接受GLP-1RAs治疗分为两组：对照组和GLP-1RA组。采用倾向评分匹配法（PSM）以1:1的比例匹配对照组。使用生存曲线以及单因素和多因素Cox回归分析来比较GLP-1RA治疗对预后的影响。
共纳入981例患者，277对（554例患者）进行了倾向评分匹配。PSM后两组间的平衡性得到改善（>0.05）。与对照组相比，GLP-1RA组患者的总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）和糖化血红蛋白（HbA1c）水平较低（<0.05）。随访24个月后，共有93例患者发生心血管不良事件。生存曲线显示，GLP-1RA组的无事件生存率高于对照组（对数秩检验=0.012）。单因素和多因素Cox回归分析显示，体重指数（BMI）（风险比[HR]：1.055，95%置信区间[CI]=1.007-1.105）、高密度脂蛋白胆固醇（HDL-C）水平（HR：0.236，95%CI=0.095-0.583）和GLP-1RA的使用（HR：0.617，95%CI=0.403-0.943）是T2DM患者PCI术后主要不良心血管事件（MACE）风险的独立影响因素（<0.05）。
GLP-1RA治疗对PCI术后的T2DM患者具有心血管益处，可有效降低MACE风险，改善长期预后。
